Haisco Pharmaceutical Group Co., Ltd. (002653.SZ)
CNY 42.8
(-0.23%)
CNY 42.8
(-0.23%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 313.53 Million CNY | -15.84% |
| 2022 | 364.44 Million CNY | -28.86% |
| 2021 | 512.25 Million CNY | -26.69% |
| 2020 | 698.79 Million CNY | 27.8% |
| 2019 | 546.79 Million CNY | 68.78% |
| 2018 | 323.96 Million CNY | 21.81% |
| 2017 | 265.96 Million CNY | -23.55% |
| 2016 | 347.88 Million CNY | -14.12% |
| 2015 | 405.08 Million CNY | -10.88% |
| 2014 | 454.51 Million CNY | -1.47% |
| 2013 | 461.29 Million CNY | 32.25% |
| 2012 | 348.81 Million CNY | 21.38% |
| 2011 | 287.36 Million CNY | -1.15% |
| 2010 | 290.69 Million CNY | 7.92% |
| 2009 | 269.35 Million CNY | 29.91% |
| 2008 | 207.34 Million CNY | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q3 | 296.44 Million CNY | 278.23% |
| 2024 Q1 | 64.84 Million CNY | -34.4% |
| 2024 Q2 | 78.37 Million CNY | 20.87% |
| 2023 Q4 | 98.84 Million CNY | -28.6% |
| 2023 FY | 306.7 Million CNY | -15.84% |
| 2023 Q1 | 26.29 Million CNY | -90.62% |
| 2023 Q2 | 35.38 Million CNY | 34.56% |
| 2023 Q3 | 138.42 Million CNY | 291.26% |
| 2022 FY | 364.44 Million CNY | -28.86% |
| 2022 Q2 | 34.01 Million CNY | 34.8% |
| 2022 Q4 | 280.39 Million CNY | 1030.7% |
| 2022 Q3 | 24.79 Million CNY | -27.09% |
| 2022 Q1 | 25.23 Million CNY | -65.64% |
| 2021 Q3 | -46.28 Million CNY | -350.55% |
| 2021 Q4 | 73.43 Million CNY | 258.67% |
| 2021 FY | 512.25 Million CNY | -26.69% |
| 2021 Q1 | 466.62 Million CNY | 75.32% |
| 2021 Q2 | 18.47 Million CNY | -96.04% |
| 2020 Q4 | 266.15 Million CNY | 38.49% |
| 2020 Q1 | 132.7 Million CNY | 10.95% |
| 2020 Q3 | 192.18 Million CNY | 78.37% |
| 2020 FY | 698.79 Million CNY | 27.8% |
| 2020 Q2 | 107.74 Million CNY | -18.81% |
| 2019 Q1 | 56.84 Million CNY | 338.21% |
| 2019 Q3 | 163.75 Million CNY | -20.73% |
| 2019 Q4 | 119.61 Million CNY | -26.96% |
| 2019 FY | 546.79 Million CNY | 68.78% |
| 2019 Q2 | 206.57 Million CNY | 263.37% |
| 2018 Q2 | 79.45 Million CNY | 13.92% |
| 2018 Q4 | 12.97 Million CNY | -91.98% |
| 2018 FY | 323.96 Million CNY | 21.81% |
| 2018 Q1 | 69.74 Million CNY | 120.99% |
| 2018 Q3 | 161.78 Million CNY | 103.62% |
| 2017 Q1 | 38.92 Million CNY | -49.19% |
| 2017 FY | 265.96 Million CNY | -23.55% |
| 2017 Q2 | 111.27 Million CNY | 185.84% |
| 2017 Q4 | 31.56 Million CNY | -62.52% |
| 2017 Q3 | 84.2 Million CNY | -24.33% |
| 2016 Q3 | 80.03 Million CNY | -44.86% |
| 2016 Q1 | 46.09 Million CNY | -53.08% |
| 2016 Q4 | 76.61 Million CNY | -4.27% |
| 2016 FY | 347.88 Million CNY | -14.12% |
| 2016 Q2 | 145.14 Million CNY | 214.84% |
| 2015 Q4 | 98.26 Million CNY | 40.72% |
| 2015 Q3 | 69.82 Million CNY | -44.25% |
| 2015 Q2 | 125.25 Million CNY | 12.09% |
| 2015 Q1 | 111.73 Million CNY | 7.84% |
| 2015 FY | 405.08 Million CNY | -10.88% |
| 2014 Q2 | 126.38 Million CNY | 43.28% |
| 2014 FY | 454.51 Million CNY | -1.47% |
| 2014 Q4 | 103.61 Million CNY | -23.98% |
| 2014 Q3 | 136.3 Million CNY | 7.85% |
| 2014 Q1 | 88.2 Million CNY | -35.3% |
| 2013 Q2 | 128.74 Million CNY | 81.42% |
| 2013 Q4 | 136.33 Million CNY | 8.84% |
| 2013 FY | 461.29 Million CNY | 32.25% |
| 2013 Q1 | 70.96 Million CNY | -39.12% |
| 2013 Q3 | 125.25 Million CNY | -2.71% |
| 2012 FY | 348.81 Million CNY | 21.38% |
| 2012 Q2 | 95.11 Million CNY | 166.75% |
| 2012 Q3 | 101.47 Million CNY | 6.69% |
| 2012 Q4 | 116.56 Million CNY | 14.87% |
| 2012 Q1 | 35.65 Million CNY | -69.47% |
| 2011 FY | 287.36 Million CNY | -1.15% |
| 2011 Q4 | 116.79 Million CNY | 94.87% |
| 2011 Q3 | 59.93 Million CNY | -25.82% |
| 2011 Q2 | 80.79 Million CNY | 170.83% |
| 2011 Q1 | 29.83 Million CNY | -70.73% |
| 2010 Q3 | 66.44 Million CNY | 0.0% |
| 2010 FY | 290.69 Million CNY | 7.92% |
| 2010 Q4 | 101.92 Million CNY | 53.4% |
| 2009 FY | 269.35 Million CNY | 29.91% |
| 2008 FY | 207.34 Million CNY | 0.0% |